Literature DB >> 28596646

Evaluation of Bone Marrow Microvessel Density in Patients with Aplastic Anemia.

Venkatesan Somasundaram1, Manvir Singh Tevatia2,3, Abhishek Purohit4, Ankur Ahuja5, Manoranjan Mahapatra5, Seema Tyagi5, Haraprasad Pati5, Renu Saxena5.   

Abstract

Bone marrow microenvironment plays a crucial role in the growth of hemopoietic cells and bone marrow function, which in turn depends on an intact microvasculature. Our study assesses the microvessel density (MVD) in the bone marrow of aplastic anemia (AA) patients, compares with MVD of controls and MVD among the different types of AA. Bone marrow specimens from 60 patients with AA and 17 controls were studied. There were 33 patients with non severe AA (NSAA), 12 patients with severe AA (SAA) and 15 patients with very severe AA (VSAA). MVD was calculated on sections stained immunohistochemically for CD34. The mean bone marrow MVD in AA group was 1.28 ± 0.36, being significantly lower than that in control group (6.80 ± 1.59, p < 0.001). MVD of SAA and NSAA patients were 1.16 ± 0.35 and 1.49 ± 0.27, respectively, being significantly different (p = 0.003). MVD of VSAA was 0.93 ± 0.25 and the difference with NSAA is significant, however there was no significant difference between SAA and VSAA. Bone marrow MVD is low in AA patients and is likely to have a role in pathophysiology of bone marrow failure. Proangiogenic agents together with specific therapy might accelerate the recovery of hematopoiesis in AA patients.

Entities:  

Keywords:  Angiogenesis; Aplastic anemia; CD 34; Mean vascular density (MVD)

Year:  2016        PMID: 28596646      PMCID: PMC5442054          DOI: 10.1007/s12288-016-0707-6

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  25 in total

Review 1.  What is the definition of cure for aplastic anemia?

Authors:  B M Camitta
Journal:  Acta Haematol       Date:  2000       Impact factor: 2.195

2.  Selection of patients for bone marrow transplantation in severe aplastic anemia.

Authors:  B M Camitta; J M Rappeport; R Parkman; D G Nathan
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

Review 3.  The pathophysiology of acquired aplastic anemia.

Authors:  N S Young; J Maciejewski
Journal:  N Engl J Med       Date:  1997-05-08       Impact factor: 91.245

4.  Alterations in hematopoietic microenvironment in patients with aplastic anemia.

Authors:  Irina N Shipounova; Tatiana V Petrova; Daria A Svinareva; Kira S Momotuk; Elena A Mikhailova; Nina I Drize
Journal:  Clin Transl Sci       Date:  2009-02       Impact factor: 4.689

5.  Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia.

Authors:  Wolfgang Füreder; Maria-Theresa Krauth; Wolfgang R Sperr; Karoline Sonneck; Ingrid Simonitsch-Klupp; Leonhard Müllauer; Michael Willmann; Hans-Peter Horny; Peter Valent
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

6.  Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death.

Authors:  C Selleri; T Sato; S Anderson; N S Young; J P Maciejewski
Journal:  J Cell Physiol       Date:  1995-12       Impact factor: 6.384

7.  Alteration in marrow stromal microenvironment and apoptosis mechanisms involved in aplastic anemia: an animal model to study the possible disease pathology.

Authors:  Sumanta Chatterjee; Ranjan Kumar Dutta; Pratima Basak; Prosun Das; Madhurima Das; Jacintha Archana Pereira; Malay Chaklader; Samaresh Chaudhuri; Sujata Law
Journal:  Stem Cells Int       Date:  2010-09-19       Impact factor: 5.443

Review 8.  Aplastic anaemia: a review.

Authors:  S Sleijfer; P J Lugtenburg
Journal:  Neth J Med       Date:  2003-05       Impact factor: 1.422

9.  Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study.

Authors: 
Journal:  Blood       Date:  1987-12       Impact factor: 22.113

10.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.

Authors:  Norbert Frickhofen; Hermann Heimpel; Joachim P Kaltwasser; Hubert Schrezenmeier
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

View more
  1 in total

Review 1.  Role of the microenvironment in myeloid malignancies.

Authors:  Marie Goulard; Christine Dosquet; Dominique Bonnet
Journal:  Cell Mol Life Sci       Date:  2017-12-08       Impact factor: 9.261

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.